UPL to launch new insecticide with patented AI Flupyrimin in India for paddy

Share this

10 June 2022, London: UPL Ltd., a global provider of sustainable agricultural solutions, today announced that it would launch new insecticides in India containing the patented active ingredient Flupyrimin to target the most damaging rice pests. The launch will coincide with the Kharif crop sowing season, typically starting in June, with rice the most important crop sown at this time. 

Flupyrimin is a novel insecticide with unique biological properties and residual control, effective against major rice pests such as brown plant hopper (BPH) and yellow stem borer (YSB). Extensive demonstration trials have shown that Flupyrimin protect rice yields from YSB & BPH damage and boost crop health, further supporting farmers’ economic resilience and productivity. Flupyrimin is also effective on pest populations resistant to existing insecticides.

Mike Frank, President and COO at UPL, said: “Flupyrimin is a breakthrough technology promising a leap forward in pest management for rice growers. With market access maximised through UPL’s wide-ranging distribution channels and differentiated branding strategy, the introduction of Flupyrimin in India marks another fundamental milestone of our collaboration with MMAG under our OpenAg® vision.”

Ashish Dobhal, UPL Region Head for India, said: “India is the world’s second largest producer of rice and the largest exporter of this staple crop. Growers here have been waiting for a one-shot solution to protect against pests, giving them peace of mind during the most critical growth stages of their paddy fields. Through Flupyrimin 2%GR, UPL is delivering top-of-the-industry control of YSB and BPH, while Flupyrimin 10%SC targets BPH at a later stage.”

Flupyrimin was discovered through a collaboration between MMAG and the Prof. Kagabu group. It was first registered in Japan in 2019.

Also Read: Crop Care Federation of India (CCFI) launches latest video on farmer welfare & training programs

Share this

Leave a Reply

Your email address will not be published.